{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:35:58Z","timestamp":1785440158866,"version":"3.56.0"},"reference-count":35,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T00:00:00Z","timestamp":1766880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T00:00:00Z","timestamp":1766880000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Triclabendazole (TCLZ) is a halogenated benzimidazole anthelmintic widely used in humans and animals to treat fascioliasis which acts by disrupting microtubule\u2010dependent processes in the species of\n                    <jats:italic>Fasciola<\/jats:italic>\n                    . This study aims to characterize TCLZ's degradation profile under different degradation conditions and assess the toxicological potential of its degradation products (DPs). TCLZ was subjected to forced degradation as required by the ICH Q1A(R2) and Q1B guidelines, including oxidation (H\n                    <jats:sub>2<\/jats:sub>\n                    O\n                    <jats:sub>2<\/jats:sub>\n                    ), photolysis (UV and visible light), thermal, and hydrolysis (acidic, basic, and neutral) conditions. Reverse\u2010phase high\u2010performance liquid chromatography (RP\u2010HPLC) was used to resolve DPs with Agilent Eclipse C18 column (4.6\u2009\u00d7\u2009250\u2009mm, 5\u2009\u03bcm) and the mobile phase consisting of 0.1% acetic acid (Solvent A) and methanol (Solvent B). TCLZ is susceptible to oxidative and photolytic (UV) degradation, leading to four DPs. The observed DPs were structurally characterized by liquid chromatography\u2010high\u2010resolution mass spectrometry (LC\u2010HRMS), and the corresponding fragmentation pathways were proposed.\n                    <jats:italic>In silico<\/jats:italic>\n                    tools like Zeneth, DEREK Nexus, and ADMET Predictor were used in the study. Zeneth was used to predict the probable degradation pathway of TCLZ. Three experimentally observed DPs matched with the Zeneth predictions. The toxicity of TCLZ and its DPs was predicted using\n                    <jats:italic>in silico<\/jats:italic>\n                    tools like DEREK Nexus and ADMET Predictor.\n                  <\/jats:p>","DOI":"10.1002\/bmc.70331","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T05:47:28Z","timestamp":1766987248000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrative Study on Triclabendazole Stability: Forced Degradation and\n                    <i>In Silico<\/i>\n                    Toxicity Prediction of Degradation Products"],"prefix":"10.1002","volume":"40","author":[{"given":"Kavita","family":"Pimpre","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research  Hyderabad Telangana India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sowmya","family":"Chaganti","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research  Hyderabad Telangana India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Khemchandani","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research  Hyderabad Telangana India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushpa","family":"Pilli","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research  Hyderabad Telangana India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemasree","family":"Kommalapati","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research  Hyderabad Telangana India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6389-5994","authenticated-orcid":false,"given":"Gananadhamu","family":"Samanthula","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research  Hyderabad Telangana India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,28]]},"reference":[{"issue":"18","key":"e_1_2_9_2_1","first-page":"894","article-title":"Forced Degradation Studies on Linagliptin Tablets by Reverse Phase HPLC Method","volume":"13","author":"Ashok P. K.","year":"2024","journal-title":"World Journal of Pharmaceutical Research"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13065-023-01087-x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/9781439801802"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpbao.2025.100085"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.5180"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmd.2025.100161"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2174\/15680266113139990033"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69970-4"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jpca.9b06716"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2013.06.005"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/trstmh\/trz093"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/sscp.202400195"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.3c00344"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/tx2000398"},{"key":"e_1_2_9_16_1","volume-title":"Stability Testing of New Drug Substances and Products Q1A(R2)","author":"ICH","year":"2003"},{"key":"e_1_2_9_17_1","volume-title":"Photostability Testing of New Drug Substances and Products Q1B","author":"ICH","year":"2005"},{"issue":"6","key":"e_1_2_9_18_1","article-title":"Forced Degradation Studies","volume":"3","author":"Iram F.","year":"2016","journal-title":"Journal of Analytical & Pharmaceutical Research"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00888-w"},{"key":"e_1_2_9_20_1","unstructured":"Janzen H.2016. \u201cForced Degradation Studies\u2013Comparison Between ICH EMA FDA and WHO Guidelines and ANVISA's Resolution RDC 53\/2015.\u201d Master Dissertation Universit\u00e4t Bonn."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.14.12.1513"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2004.02.038"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9081697"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1134\/S106193482570011X"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116221"},{"issue":"6","key":"e_1_2_9_26_1","first-page":"21","article-title":"Review on Development of Forced Degradation Studies and Its Approaches on Stability Indicating Method","volume":"2","author":"Rathod S. J.","year":"2019","journal-title":"Journal for Innovative Development in Pharmaceutical and Technical Science"},{"issue":"5","key":"e_1_2_9_27_1","first-page":"238","article-title":"Forced Degradation Studies for Drug Substances and Drug Products\u2010Scientific and Regulatory Considerations","volume":"7","author":"Rawat T.","year":"2015","journal-title":"Journal of Pharmaceutical Sciences and Research"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0027-5107(98)00068-2"},{"key":"e_1_2_9_29_1","first-page":"1","article-title":"Stress Test to Determine Inherent Stability of Drugs","volume":"4","author":"Singh S.","year":"2000","journal-title":"Pharmaceutical Technology"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/em.20013"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.2174\/0113892002270798231201111422"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2019.55.12.3058861"},{"issue":"3","key":"e_1_2_9_33_1","first-page":"34","article-title":"Basic Concept of Stability Profile and Stress Degradation Pathway of Pharmaceutical Formulations: A Review","volume":"4","author":"Thorat S. S.","year":"2018","journal-title":"J Biol Chem Chron"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2018.05.040"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2006.00735.x"},{"key":"e_1_2_9_36_1","unstructured":"WHO.2009.The Guidance on Stability Testing of Active Pharmaceutical Ingredients and Finished Pharmaceutical Products Was Published as Annex 2 in the World Health Organization (WHO) Technical Report Series No. 953."}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.70331","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bmc.70331","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.70331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T03:55:19Z","timestamp":1769831719000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.70331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,28]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/bmc.70331"],"URL":"https:\/\/doi.org\/10.1002\/bmc.70331","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"value":"0269-3879","type":"print"},{"value":"1099-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,28]]},"assertion":[{"value":"2025-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70331"}}